Loading clinical trials...
Loading clinical trials...
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escala...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Institut de Recherches Internationales Servier
Collaborators
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT07223021 · B-cell Acute Lymphoblastic Leukemia
NCT05674175 · B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
NCT07429461 · B-Cell Acute Lymphoblastic Leukemia
Massachusetts General Hospital
Boston, Massachusetts
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
University of Texas MD Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions